Investigating the immune response to HPV vaccines
Official title: HPV Serology
Funded at Leidos Biomedical Research, INC. · NIH-11219752 · Data updated 2026-11-12
This study is looking at how well different HPV vaccines work by checking the immune response they create, especially against high-risk types like HPV 16 and 18, to see if just one dose could be as effective as the usual three doses, which could help improve vaccination methods and better protect against cervical cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Leidos Biomedical Research, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | September 28, 2024 |
| Project end | August 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,106,553 |
| NIH project number | 75N91019D00024-0-759102400011-8 |
| Project ID | NIH-11219752 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are eligible for HPV vaccination or those who have received the vaccine and are interested in understanding their immune response.
✕Less likely to help
Patients who have already been diagnosed with cervical cancer or those who are not eligible for HPV vaccination may not benefit from this research.
What this research studies
This research focuses on understanding the immune response generated by different HPV vaccines, specifically looking at the antibodies produced against high-risk HPV types like HPV 16 and HPV 18. The study aims to establish standardized serological measures to evaluate vaccine efficacy, which is currently complicated by the use of pooled human serum as a reference. By developing a new calibration method for measuring vaccine-induced immunity, the research hopes to clarify whether a single dose of the vaccine could be as effective as the standard three-dose regimen. This could lead to improved vaccination strategies and better protection against cervical cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccination protocols against HPV, potentially reducing the incidence of cervical cancer.
How similar studies have gone: Previous research has shown promise in evaluating vaccine efficacy through serological measures, but this approach aims to establish a novel calibration standard that has not been extensively tested.
Where this research is happening
-
Leidos Biomedical Research, INC.
Frederick, United States Active
Researchers
- Principal investigator: Briscoe, Lynn — Leidos Biomedical Research, INC.
- Study coordinator: Briscoe, Lynn
Related research
Other NIH-funded projects on the same topics.
-
Improving public health responses to COVID-19 through standardized testing.
This study is looking to improve how we fight COVID-19 by testing blood samples to see if people have had the virus, and it’s designed for anyone interested in better ways to manage the disease.
-
Creating a large library of cancer models for research use
This study is creating a collection of new cancer models to help researchers and companies find better ways to treat cancer, making it easier for everyone to work together and share ideas.
-
Advancing global cancer control through data analysis and international collaboration
This study is all about helping countries around the world work better together to fight cancer by sharing important information and training scientists, especially in places that need extra support.
-
Support for HIV and HPV cancer prevention clinical trials in the Americas
This study is working on new vaccines and treatments to help prevent cancers related to HIV and HPV, making sure that patients in the US, Latin America, and the Caribbean can access better options as these exciting trials move forward.
-
Development and production of clinical-grade biopharmaceuticals
This study is all about making safe and effective new medicines, like vaccines and treatments for various conditions, so that patients can have access to the latest therapies that meet high-quality standards.
-
Understanding the immune response to COVID-19
This study is looking for ways to improve COVID-19 testing and understand how our immune system fights the virus, and you can help by sharing samples to make these tests better for everyone.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.